Abstract
Cancer treatment is slowly shifting from an approach in which the tissue of origin and the histology were the guiding principles for the choice of chemotherapy towards a genotype-centric approach in which the changes in the cancer genome are used to select patients for treatment with highly selective and targeted drugs. This transition has all the hallmarks of a disruptive innovation and requires major adjustments in the way that cancer is diagnosed and treated. We discuss here the hurdles on the road ahead to a more personalized treatment of cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 935-9 |
| Number of pages | 5 |
| Journal | Molecular Oncology |
| Volume | 9 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2015 |